Related Experiment Videos
Interleukin-2-induced antinociception in morphine-insensitive rats
Ping Song1, Xin-Yuan Liu, Zhi-Qi Zhao
1Institute of Neurobiology, Fudan University, Shanghai 200433, China.
Acta Pharmacologica Sinica
|November 8, 2002
Summary
Interleukin-2 (IL-2) provides pain relief in normal rats and even in those with morphine-insensitivity. This suggests IL-2 could be a potential therapeutic for chronic pain conditions.
Area of Science:
- Immunology
- Neuroscience
- Pain Research
Background:
- Opioid analgesics are standard for pain management.
- Morphine insensitivity presents a significant clinical challenge.
- Interleukin-2 (IL-2) is an immunomodulatory cytokine with potential analgesic properties.
Purpose of the Study:
- To evaluate the antinociceptive effects of IL-2.
- To investigate IL-2's efficacy in a model of morphine-insensitive pain.
Main Methods:
- Paw withdrawal latency (PWL) to radiant heat was used to measure pain threshold.
- Experiments were conducted on normal rats and rats with chronic pain induced by Complete Freund's Adjuvant (CFA).
- The effects of intraplantar IL-2 injection were assessed, with naloxone used to probe opioid receptor involvement.
Main Results:
- Intraplantar IL-2 significantly increased PWL in normal rats.
- IL-2 also increased PWL in CFA-treated rats, demonstrating antinociception in a morphine-insensitive model.
- IL-2-induced antinociception was less potent in CFA-treated rats compared to normal rats.
- Naloxone partially blocked IL-2's antinociceptive effect in normal rats but not in CFA-treated rats.
Conclusions:
- IL-2-induced antinociception is partly mediated by mu-opioid receptors.
- IL-2 shows promise for managing morphine-insensitive pain.
- Further research into IL-2 as an analgesic is warranted.